We are producing a mucosal vaccine delivery system which utilizes the unique features of viral proteins to delivery DNA vaccines to the mucosal surfaces. The key features of this system that will lend themselves to DNA vaccine delivery are: 1) capacity to transport DNA; 2) the lack of size restriction, and therefore the potential capacity to carry any size gene; 3) the lack of viral genes and therefore virulence; 4) the enhanced ability to enter cells and deliver DNA; 5) the elimination of problems associated with needle injections; and 6)the targeting of DNA vaccine delivery to the mucosal surfaces, where most pathogens initiate their infectious cycle.

Proposed Commercial Applications

Potential application of this system is targeted DNA vaccine delivery to mucosal surfaces.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41AI047629-01
Application #
6143893
Study Section
Special Emphasis Panel (ZRG1-VACC (02))
Program Officer
Muszynski, Karen
Project Start
2000-05-10
Project End
2002-04-30
Budget Start
2000-05-10
Budget End
2002-04-30
Support Year
1
Fiscal Year
2000
Total Cost
$99,938
Indirect Cost
Name
Agrivax, Inc.
Department
Type
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90033